GLP-1 receptor agonists like semaglutide and tirzepatide trigger adipocyte browning with UCP1 upregulation, enhanced lipolysis through ATGL and HSL enzymes, and shift stem cells toward thermogenic beige fat rather than stable white fat. These mechanisms directly oppose the biological requirements for successful fat graft survival in cosmetic procedures. The irony is profound: millions using GLP-1 drugs for weight loss develop facial volume depletion requiring fat grafting, yet the same medications may undermine the procedure's success. This represents a significant clinical blind spot as aesthetic surgery increasingly intersects with the obesity medicine boom. The emerging triple agonist retatrutide compounds concerns through additional glucagon receptor-mediated lipolysis. While no studies have directly tested fat graft outcomes in GLP-1 users, the mechanistic interference appears substantial enough to warrant perioperative medication management protocols. This finding highlights how revolutionary weight-loss therapies can create unexpected downstream complications in adjacent medical fields, potentially requiring new treatment paradigms as these drugs become standard care.